<DOC>
	<DOC>NCT00438360</DOC>
	<brief_summary>The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.</brief_summary>
	<brief_title>Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criteria: Outpatients 18 years of age and older (max 65 years) Patients with chronic plaque psoriasis on disease remission (i.e. PASI ≤75% of PASI before cyclosporine continuous treatment course) entering a maintenance period Disease remission obtained with only cyclosporine as systemic therapy (maximum dose 5 mg/kg/day) for &gt;8 weeks and &lt;16 weeks PASI still &lt;75% of PASI before cyclosporine continuous treatment course, at randomization to study treatment (8±2 days after disease remission) Exclusion criteria: Abnormal renal function (creatinine ≥ 10% the upper limit of the reference range) Severe chronic degenerative diseases Severe uncontrolled hypertension Body weigh &gt;110 kg Abnormal liver function Hyperkalemia or hyperuricemia Clinically significant impairment of hematopoietic and cardiovascular function Concomitant therapy with nephrotoxic medications Patients with malignancy or a history of malignancy Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception Clinically significant uncontrolled bacterial, viral or fungal infection Evidence of drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cyclosporine, chronic plaque psoriasis, intermittent therapy</keyword>
</DOC>